Manjaro (GIP/GLP-1 receptor agonist)

The risk of hypoglycemia with Manjaro is considered relatively low. However, if excessive dietary restrictions are implemented alongside Manjaro use, symptoms such as dizziness, fatigue, and palpitations may occur as signs of hypoglycemia. If you experience any of these symptoms, consult your doctor immediately. Additionally, be sure to inform your doctor beforehand if you have a medical history or are taking other medications.

The Manjaro needle is thin and short, so the pain is minimal. However, pain perception varies from person to person; some may feel no pain at all, while others may feel a slight discomfort.

Mangaro suppresses gastrointestinal activity, which may reduce appetite but can also cause gastrointestinal symptoms such as loss of appetite or nausea. The severity and duration of side effects vary from person to person, but digestive symptoms tend to occur more frequently shortly after starting treatment. If you experience any concerning symptoms, please consult your doctor.

Do not stop using the medication on your own; consult your doctor. These are generally temporary side effects that usually lessen as your body adjusts to the medication. However, if you experience severe symptoms, seek immediate medical attention.

The difference between Mangalor and other GLP-1 receptor agonists lies in the number of hormones they target. GLP-1 receptor agonists act only on GLP-1, while Mangalor acts on both GLP-1 and GIP. Therefore, Mangalor is expected to be more effective than conventional GLP-1 receptor agonists. Research also suggests it is less likely to cause side effects such as gastrointestinal symptoms.

Mangaro cannot be purchased outside of medical institutions. You can only purchase it after receiving a doctor's examination and being deemed suitable for the medication. Please avoid using personal imports from overseas or online retailers, as these offer no guarantee of quality despite being cheaper.

Mangarlo has weight-loss effects and cannot be prescribed to individuals with a BMI of 22 or below. Additionally, if you are taking other diabetes medications besides Mangarlo, there is a risk of hypoglycemia. Always inform your doctor before taking it and avoid combining medications on your own. Furthermore, it may not be prescribed if you have severe gastrointestinal disorders, as it could potentially affect the digestive system. If you have any other medical history or are taking other medications, please inform your doctor during your consultation.

The timing of when you notice the effects varies from person to person, but it's common to feel a decrease in appetite several weeks after starting treatment. Blood sugar levels also tend to improve within about one to two weeks.

Mangaro is a medication administered on the same day each week. If you miss a dose or forget to administer it, and there are 3 days (72 hours) or more until the next scheduled dose, administer it immediately and then administer the next dose on the scheduled day. If there are less than 3 days (72 hours) until the next scheduled dose, do not administer it immediately; instead, administer it on the next scheduled day.

Mangaro is covered by insurance as a treatment for type 2 diabetes. For obesity, it is not covered by insurance and requires out-of-pocket payment.

Other diabetes medications besides Manjaro include insulin injections. This method involves injecting artificially produced insulin to supplement insulin levels. Manjaro is a medication that works by stimulating insulin secretion and is different from insulin injections.

Manjaro is a peptide hormone, and its effectiveness may be compromised by high temperatures or direct sunlight, so extreme care must be taken with storage. It should generally be stored in a refrigerator, taking care to avoid freezing. If a refrigerator is unavailable, it can be stored at room temperature below 30°C for up to 21 days.